Recent news on Novantrone

Gain Insight into Upcoming Treatments for Multiple Sclerosis with ...  -  May 17, 2007
Genetic Engineering News (press release),Copaxone, Novantrone, and Tysabri. Dosing and drug storage and preparation information is provided, along with the annual cost for each therapy.

Colorado BioScience Association Names Jack Wheeler Chairperson ...  -  May 21, 2007
dBusinessNews Denver (press release),He served as Project Head for the Team that licensed the oncology rights to Novantrone from Serono. As Senior Director, Marketing and Sales,

Mitoxantrone Can Extend Time to Disease Progression in Worsening ...  -  May 7, 2007
DG NewsBOSTON, MA -- May 7, 2007 -- The results of the Registry to Evaluate Novantrone Effects in Worsening MS (RENEW) study continue to demonstrate the benefits

OSI Pharmaceuticals Announces First Quarter 2007 Financial Results  -  Apr 27, 2007
PharmaLive.com (press release),Offsetting these increases was a decline in commissions related to sales of Novantrone(R) (mitoxantrone for injection concentrate) which lost patent

MS Patients Not Receiving Medications To Slow Disease Progression ...  -  Apr 20, 2007
Medical News Today (press release),...interferon-1a (Avonex®), glatiramer acetate (GA or Copaxone®), interferon-1a (Rebif®), mitoxantrone (Novantrone®) and natalizumab (Tysabri®).

BTG signs agreement with Novacea and KuDOS for AQ4N  -  Apr 19, 2007
PharmaLive.com (press release),...potent cytotoxicity comparable to other marketed Topoisomerase II inhibitors such as Novantrone(r) (mitoxantrone) and Adriamycin(r) (doxorubicin).

Novacea Acquires Worldwide Development and Commercialization ...  -  Apr 19, 2007
SYS-CON Media,...exhibits potent cytotoxicity comparable to other marketed Topoisomerase II inhibitors such as Novantrone® (mitoxantrone) and Adriamycin® (doxorubicin).

MS patients not receiving medications to slow disease progression  -  Apr 18, 2007
News-Medical.net,...interferon-1a (Avonex), glatiramer acetate (GA or Copaxone), interferon-1a (Rebif), mitoxantrone (Novantrone) and natalizumab (Tysabri).

Long-term Results Confirm Taxotere® Improves Survival in ...  -  Feb 27, 2007
Cancer Consultants (press release),TAX 327 was a Phase III clinical trial to directly compare Taxotere-prednisone to Novantrone® (mitoxantrone)-prednisone in the treatment of 1006 men with

BioMS Medical: potential to broaden MS treatment options  -  Mar 2, 2007
Pharmaceutical Business ReviewLike Novantrone (and natalizumab; marketed as Tysabri by Biogen Idec and Elan), MBP-8298 is administered by intravenous infusion.

Survival hope for patients with metastatic prostate cancer  -  Mar 4, 2007
TopCancerNews.com,A Phase III clinical trial named TAX 327 compared Taxotere plus prednisone to Novantrone (mitoxantrone) plus prednisone. The study included a little over a

OSI Pharmaceuticals Announces Year End 2006 Financial Results  -  Feb 23, 2007
Oxfordshire Bioscience Network (press release),...respectively, including sales commissions from oncology sales of Novantrone(R), license fees, milestones, and collaborative program revenues.

Specialty Infusion Brings New Challenges, Solutions to Payers  -  Feb 12, 2007
Atlantic Information Services, Inc.,...under which drugs such as Remicade (infliximab), Novantrone (mitoxantrone), Flolan (epoprostenol sodium) and Remodulin (treprostinil sodium) fall.

Mitoxantrone-based Therapy Increases Risk for Subsequent Leukemia ...  -  Jan 12, 2007
Cancer Consultants (press release),According to an early online publication from the Journal of Clinical Oncology, the use of the chemotherapy agent Novantrone® (mitoxantrone) to treat breast

Merck Serono Completes Patient Enrollment in CLARITY Phase III ...  -  Jan 16, 2007
Drug Newswire (press release),In addition to Rebif(R), the Company also offers a second therapy within its US portfolio of MS therapies: Novantrone(R) (mitoxantrone for injection

Fludara®-Novantrone® Induction and Zevalin® Consolidation Results ...  -  Dec 19, 2006
Cancer Consultants (press release),Researchers from Italy have reported a 100% complete response (CR) rate to induction therapy with oral Fludara (fludarabine) and Novantrone (mitoxantrone)

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 12, 2006
Drug Newswire (press release),In addition to Rebif(R), Serono also offers a second therapy within its US portfolio of multiple sclerosis (MS) therapies: Novantrone(R) (mitoxantrone for

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 11, 2006
Yahoo! News (press release)In addition to Rebif®, Serono also offers a second therapy within its US portfolio of multiple sclerosis (MS) therapies: Novantrone® (mitoxantrone for

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  Dec 11, 2006
PR Newswire (press release),...therapy within its US portfolio of multiple sclerosis (MS) therapies: Novantrone(R) (mitoxantrone for injection concentrate) for worsening forms of MS.

Aggressive Treatment of PSA Recurrences After Primary Treatment Is ...  -  Dec 6, 2006
Cancer Consultants (press release),Currently, only three drugs, Taxotere, Emcyt and Novantrone® (mitoxantrone), are FDA-approved for the treatment of prostate cancer.

OSI Pharmaceuticals Announces Third Quarter 2006 Financial Results  Nov 6, 2006
...$11.1 million for the three months ended September 30, 2006 and 2005, respectively, including sales commissions from oncology sales of Novantrone(R), license ... -Genetic Engineering News (press release), OSI Pharmaceuticals Announces Third Quarter 2006 Financial Results  Nov 6, 2006
...million for the three months ended September 30, 2006 and 2005, respectively, including sales commissions from oncology sales of Novantrone®, license fees ... -Business Wire (press release), Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
Novantrone(R) sales in the third quarter of 2006 were $2.8m, down 84.6%, consequent to the introduction of generics of mitoxantrone in the US in April 2006 (Q3 ... -MSN Money Serono posts better-than-forecast Q3 results, driven by MS drug ...  Oct 19, 2006
Cladribine treatment Novantrone sales in the third quarter were 2.8 mln usd, down 84.6 pct hit by the introduction of generics in the US in April 2006. ... -Forbes, Serono Q3 Adj. Profit Rises 15.5% On Strong Sales Of Rebif And ...  Oct 19, 2006
The once-in-three month drug, Novantrone, for reducing neurologic disability, generated third quarter sales of $2.8 million, down 84.6% from $18.2 million a ... -Trading Markets, Serono Delivers Strong Adjusted* Net Income of $183.5m in Third ...  Oct 18, 2006
...than four years after launch in the US, Rebif(R) continues to grow strongly and reached US sales of $133.3m, up 30.1% (Q3 2005: $102.5m). Novantrone(R) sales ... -PR Newswire (press release), Mesothelioma Reseaerch Shows Promise  Aug 26, 2006
Italy are reporting that sequential chemotherapy with Platinol® (cisplatin) and Gemzar (gemcitabine) followed by Novantrone® (mitoxantrone), methotrexate and ... -World Fitness

Serono Announces Initiation of the Reflex Trial to Evaluate New ...  -  12 Dec 2006
Drug Newswire (press release),In addition to Rebif(R), Serono also offers a second therapy within its US portfolio of multiple sclerosis (MS) therapies: Novantrone(R) (mitoxantrone for

Tysabri is back, but Elan is down -- time to buy  Jul 27, 2006
A report touting a new therapy for multiple sclerosis patients combining Novantrone, a cancer drug, with Copaxone, hit the newswires on Friday. ... -MSN Money

Serono Delivers Second Quarter EPS of $12.92, Up 25.2% on Adjusted ...  Jul 26, 2006
...the Bourn Hall clinic management buyout and the sale of a non-core business, TerraCell SA, in 2005, as well as the introduction of generics of Novantrone(R) in ... -PharmaLive.com

Serono Q2 net profit rises 8 pct, sales disappoint - UPDATE  Jul 27, 2006
...growth drug Saizen up 0.4 pct to 53.8 mln, sales for dermatology drug Raptiva surging by 130.4 pct to 17.3 mln and sales in oncology drug Novantrone down 70.4 ... -Forbes

Serono Q2 profit rises  Jul 27, 2006
...impact on sales of the Bourn Hall clinic management buyout and the sale of TerraCell, in 2005, as well as the introduction of generics of Novantrone in early ... -Pharmaceutical Business Review

PREDICTING GROWTH: Serono’s Firouz says Biogen’s returning MS ...  Jul 28, 2006
Firouz said Tysabri would more likely compete with Serono’s Novantrone, another MS treatment that saw a 70 percent plunge in sales in the recent quarter ... -The Patriot Ledger

Researchers Report Gains Against Muscle-Wasting Disease  Jul 9, 2006
Medications like Novantrone, prednisone, cyclosporine and azathioprine keep the body from interfering with the chemical receptors controlling muscle ... -Forbes

European Commission Approves Serono's SmPC Update For Multiple ...  Jul 9, 2006
...enzymes and blood cell abnormalities. In addition to Rebif, Serono also offers Novantrone for worsening forms of MS. On the NYSE, SRA ... -Trading Markets

European Commission Approves Revision of Therapeutic Indication ...  Jul 9, 2006
In addition to Rebif®, Serono also offers a second therapy within its US portfolio of multiple sclerosis (MS) therapies: Novantrone® (mitoxantrone for ... -Yahoo! News

European Commission Approves Revision of Therapeutic Indication ...  Jul 10, 2006
In addition to Rebif(R), Serono also offers a second therapy within its US portfolio of multiple sclerosis (MS) therapies: Novantrone(R) (mitoxantrone for ... -PharmaLive.com

Team Serono gears up for Great Mass Getaway  Jun 23, 2006
Along with its MS drugs, Rebif(r) and Novantrone(r), Serono also supports MS patient initiatives, such as MS LifeLines, an educational and supportive community ... -Abington Mariner



Medicare Part D participants ask drug companies for help  May 13, 2006
Those companies are Teva Neuroscience, which makes Copaxone; Serono Inc., which makes Rebif and Novantrone; and Biogen Idec, maker of Avonex. ... - Springfield State Journal Register

OSI Pharmaceuticals Announces First Quarter 2006 Financial Results  May 8, 2006
Sales commissions of $7.1 million related to oncology sales of Novantrone. As previously communicated, future commissions are ... - Genetic Engineering News

Multiple Sclerosis: New Insights and Trends  May 10, 2006
...phase. For SPMS, the most convincing data favors mitoxantrone (Novantrone) as most likely to retard progression and delay disability. ... - AJNR (subscription)

Multiple Sclerosis Research  May 3, 2006
Researchers are studying medications such as Rolipram, Zenapax, Natalizumab, and Novantrone for treating multiple sclerosis, and non-medicine treatments such ... - About - News & Issues

Phase III Trial Of Oral Cladribine, A Novel Investigational ...  May 5, 2006
Serono has two therapies available for the treatment of MS: Rebif (interferon beta-1a), indicated for relapsing forms of MS, and Novantrone (mitoxantrone for ... - Medical News Today





Taxol® and Paraplatin® Superior to Novantrone® for Hormone ...  Mar 10, 2006
Urology, treatment consisting of Taxol® (paclitaxel) and Paraplatin® (carboplatin) provides superior outcomes compared to Novantrone® (mitroxantrone) in the ... - Cancer Consultants

Taxol® and Paraplatin® Superior to Novantrone® for Hormone ...  Mar 10, 2006
Researchers from France have reported that the combination of Taxol (paclitaxel) and Paraplatin (carboplatin) is superior to Novantrone (mitoxantrone) for the ... - Cancer Consultants

Ask The Doctor: Living With MS Today  Mar 24, 2006
St. John's Mercy Medical Center neurologist. Montileone Harms is on her second round of a chemotherapy drug called Novantrone. One ... - KSDK

MS Guessing Game Heats Up  Mar 9, 2006
...players in the MS market include Switzerland's Serono (SRA:NYSE ADR - commentary - research - Cramer's Take) which makes Rebif and Novantrone, Israel's Teva ... - TheStreet.com

Tysabri poised for return to market  Mar 31, 2006
Schering AG's Betaferon/Betaseron (interferon beta- 1b), Teva Neuroscience's Copaxone (glatiramer acetate), Serono SA's Novantrone (mitoxantrone hydrochloride ... - Pharmaceutical Business Review

Wonder drugs don’t exist for MS; stick with proven options  Mar 26, 2006
Interferon beta-1b (Betaseron), interferon beta-1a (Avonex, Rebif), glatiramer (Copaxone), and mitoxantrone (Novantrone) are only partially effective in the ... - Fort Wayne Journal Gazette



Two-Day Tysabri Hearing Drawing Intense Attention  Mar 3, 2006
1a, from Serono SA). An immunosuppressant, Novantrone (mitoxantrone, also from Serono), is used as well. Jeffrey expressed concern ... - BioWorld Online (subscription),

Xanthus' Symadex(TM) shows Remyelination in Multiple Sclerosis ...  Feb 13, 2006
Symadex was developed to deliver efficacy comparable to the anthracenediones (eg, Novantrone(R) (mitoxantrone)), but with a molecular scaffold intended to ... - Canada NewsWire,

Flat sales in Q4 for Serono; no word on buyer  Feb 6, 2006
...in the quarter, but the fall-off in sales accelerated for two of Serono's other products, Serostim (somatropin) for wasting and Novantrone (mitoxantrone) for ... - Pharma Times (subscription)

Older AML Patients Do Not Benefit From More Therapy  Jan 9, 2006
...with one of these four therapies, patients were then treated with one or two courses of the chemotherapy combination mitoxantrone (Novantrone®) plus cytarabine ... - Cancer Consultants

Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients ...  Jan 17, 2006
Symadex was developed to deliver efficacy comparable to anthracyclines (eg, doxorubicin) and anthracenediones (eg, Novantrone(R) (mitoxantrone)), but with ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional